EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
Source: EQS
EQS-Ad-hoc: Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024. Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (previously: 3 to 6%). Group EBIT at constant currency is now expected to grow between 6 and 10% (previously: 4 to 8%). The increase of the group outlook is based on improved business prospects for Fresenius Kabi. Fresenius Kabi now expects organic revenue growth in the mid to high single-digit percentage range for fiscal year 2024 (previously: mid single-digit percentage range). The EBIT margin is now expected to range between 15 and 16% (previously: around 15%). The adjustment of the group outlook also reflects the fact that the forecast is now provided without Fresenius Vamed, i.e. exclusively for the operating companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed’s rehabilitation business, Fresenius has initiated its structured exit from its investment company Fresenius Vamed. For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures. represented by The Management Board Bad Homburg v.d.H., ---------------------------------------- Contact: Senior Vice President Investor Relations T: +49 (0) 6172 608-2485 markus.georgi@fresenius.com ---------------------------------------- End of Note End of Inside Information
|
Language: | English |
Company: | |
Else-Kröner-Straße 1 | |
61352 Bad Homburg v.d.H. | |
Phone: | +49 (0)6172 608-2485 |
Fax: | +49 (0)6172 608-2488 |
E-mail: | ir-fre@fresenius.com |
Internet: | www.fresenius.com |
ISIN: | DE0005785604 |
WKN: | 578560 |
Indices: | DAX |
Listed: | Regulated Market in |
EQS News ID: | 1898031 |
End of Announcement |
|
1898031 07-May-